miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential

作者全名："Yan, Hang; Tang, Shengjie; Tang, Shoujun; Zhang, Jun; Guo, Haiyang; Qin, Chao; Hu, Haiyang; Zhong, Chuan; Yang, Li; Zhu, Yunhe; Zhou, Haining"

作者地址："[Yan, Hang; Tang, Shengjie; Tang, Shoujun; Zhang, Jun; Guo, Haiyang; Qin, Chao; Hu, Haiyang; Zhong, Chuan; Yang, Li; Zhu, Yunhe; Zhou, Haining] Chongqing Med Univ, Suining Cent Hosp, Affiliated Hosp, Dept Thorac Surg, Suining, Peoples R China; [Yan, Hang; Zhang, Jun; Qin, Chao; Hu, Haiyang; Zhou, Haining] Zunyi Med Univ, Inst Surg, Grad Sch, Zunyi, Peoples R China; [Guo, Haiyang; Zhou, Haining] Chengdu Univ TCM, Inst Surg, Grad Sch, Chengdu, Peoples R China"

通信作者："Zhu, YH; Zhou, HN (通讯作者)，Chongqing Med Univ, Suining Cent Hosp, Affiliated Hosp, Dept Thorac Surg, Suining, Peoples R China.; Zhou, HN (通讯作者)，Zunyi Med Univ, Inst Surg, Grad Sch, Zunyi, Peoples R China.; Zhou, HN (通讯作者)，Chengdu Univ TCM, Inst Surg, Grad Sch, Chengdu, Peoples R China."

来源：FRONTIERS IN PHARMACOLOGY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:000880825300001

JCR分区：Q1

影响因子：5.6

年份：2022

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：drug resistance; miRNA; NSCLC; therapy; biomarker

摘要："Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors worldwide. Clinical success is suboptimal owing to late diagnosis, limited treatment options, high recurrence rates, and the development of drug resistance. MicroRNAs (miRNAs), a range of small endogenous non-coding RNAs that are 22 nucleotides in length, have emerged as one of the most important players in cancer initiation and progression in recent decades. Current evidence has revealed the pivotal roles of miRNAs in regulating cell proliferation, migration, invasion, and metastasis in NSCLC. Recently, several studies have demonstrated that miRNAs are strongly associated with resistance to anti-cancer drugs, ranging from traditional chemotherapeutic and immunotherapy drugs to anti-vascular drugs, and even during radiotherapy. In this review, we briefly introduce the mechanism of miRNA dysregulation and resistance to anti-tumor therapy in NSCLC, and summarize the role of miRNAs in the malignant process of NSCLC. We then discuss studies of resistance-related miRNAs in chemotherapy, radiotherapy, targeted therapy, immunotherapy, and anti-vascular therapy in NSCLC. Finally, we will explore the application prospects of miRNA, an emerging small molecule, for future anti-tumor therapy. This review is the first to summarize the latest research progress on miRNAs in anti-cancer drug resistance based on drug classification, and to discuss their potential clinical applications."

基金机构：Chengdu University of Traditional Chinese Medicine; Health Department of Sichuan Province; [YYZX2020093]; [21PJ188]

基金资助正文：Funding The research was supported by Chengdu University of Traditional Chinese Medicine (YYZX2020093) and Health Department of Sichuan Province (21PJ188).